Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: An audit of adverse events and outcome

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 3, 2008, Pages 169-173

  Shah, Jayshri A ^a,d   Edwards, Cathryn M ^c   Probert, Chris S ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c TORBAY HOSPITAL   (United Kingdom)

^d NONE   (United Kingdom)

Author keywords

5 aminosalicylates; Adverse reactions; Azathioprine; Inflammatory bowel disease; Relapse

Indexed keywords

AZATHIOPRINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISEASE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; FEVER; HUMAN; INFECTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALAISE; MONOTHERAPY; PANCREATITIS; PRESCRIPTION; PRIORITY JOURNAL; RASH; RECURRENCE RISK; SIDE EFFECT; SWELLING; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 39849103868     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f16d50     Document Type: Article

References (30)

1. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl No V):v4.
2. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5- aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000; CD000543.
3. Cama C, Giunta M, Rosselli M, Cottone M. Mesalazine in the maintenance treatment of Crohns disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113:1465-1473.
4. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for inducing remission of Crohn's disease. Cochrane Database System Rev 2000; CD000067.
5. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for treatment of inflammatory bowel disease: a 30-year review. Gut 2002; 50:485-489.
6. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55:47-53.
7. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91:44.
8. Moody GA, Jayanthi V, Probert CS, MacKay H, Mayberry JF. Long term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8:1179-1183.
9. Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 2005; 100:1354-1356.
10. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16:79-85.
11. Gilissen LP, Bierau J, Derijks LJ, Bos LP, Hooymans PM, van Gennip A, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005; 22:605-611.
12. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18:395-400.
13. Lowry PW, Franklin CL, Weaver AL. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalasine, sulphasalazine, or balsalazide. Gut 2001; 49:656-664.
14. Marinaki AM, Ansari A, Duley JA, Arenes MS, Sumi SA, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14:181-187.
15. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6- mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123:132-142.
16. Jasmohan S, Bajaj MD, Saeian K, Varma RR, Jose Franco MD, Knox JF, et al. Increased rate of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005; 100:1121-1125.
17. De Jong DJ, Goullet M, Naber THJ. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2004; 16: 207-212.
18. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025-1030.
19. Xin H, Fischer C, Schwab M, Klotz U. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment pharmacol Ther 2005; 21:1105.
20. Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in Inflammatory bowel disease. World J Gastroenterol 2006; 12:3657-3667.
21. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C > A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004; 14:779-781.
22. Allorge D, Hamdoan R, Broly F, Libersa C, Colombel JF. ITPA genotyping does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 2005; 54:565.
23. Stevens T, Achkar J-P, Easley K, Brzezinski A, Lashner B. Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20:601-606.
24. Lennaed L. Clinical implications of thiopurine methyltransferase- optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20:527-531.
25. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6- mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39:456-459.
26. Mantzaris-Gerassimos J, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Angeliki K, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid dependent ulcerative colitis. The Am J Gastroenterol 2004; 99:1122-1128.
27. Munk EM, Pedersen-Lars FA, Norgard B, Rasmussen HH, Sorensen-Henrik T. Inflammatory bowel diseases, 5-aminosalicylic acid and sulphasalazine treatment and risk of acute pancreatitis: a population-based case-control study. The Am J Gastroenterol 2004; 99:884-888.
28. Rayner CK, Hart AL, Hayward CMM, Emmanuel AV, Kamm MA. Azathioprine dose escalation in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20:65-71.
29. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001; 48:591-592.
30. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001; 13:1297-1301.